Amgen Inc. (NASDAQ:AMGN) Shares Sold by St. Johns Investment Management Company LLC

St. Johns Investment Management Company LLC decreased its position in shares of Amgen Inc. (NASDAQ:AMGN) by 6.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,488 shares of the medical research company’s stock after selling 369 shares during the period. St. Johns Investment Management Company LLC’s holdings in Amgen were worth $1,768,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. BKM Wealth Management LLC lifted its holdings in Amgen by 3.0% in the 3rd quarter. BKM Wealth Management LLC now owns 6,562 shares of the medical research company’s stock valued at $2,114,000 after acquiring an additional 194 shares during the last quarter. Parcion Private Wealth LLC lifted its stake in Amgen by 83.9% during the third quarter. Parcion Private Wealth LLC now owns 2,887 shares of the medical research company’s stock valued at $930,000 after purchasing an additional 1,317 shares during the last quarter. Outlook Wealth Advisors LLC boosted its holdings in Amgen by 2.5% during the third quarter. Outlook Wealth Advisors LLC now owns 1,499 shares of the medical research company’s stock worth $483,000 after buying an additional 37 shares in the last quarter. Allworth Financial LP grew its position in Amgen by 3.2% in the third quarter. Allworth Financial LP now owns 25,033 shares of the medical research company’s stock worth $8,066,000 after buying an additional 785 shares during the last quarter. Finally, Convergence Financial LLC acquired a new position in Amgen in the third quarter worth approximately $204,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have recently weighed in on AMGN. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a $305.00 price objective (down from $310.00) on shares of Amgen in a research note on Wednesday, August 7th. Wells Fargo & Company lowered Amgen from an “overweight” rating to an “equal weight” rating and increased their price target for the company from $320.00 to $335.00 in a research report on Wednesday, August 7th. Sanford C. Bernstein initiated coverage on Amgen in a research note on Thursday, October 17th. They issued an “outperform” rating and a $380.00 price target on the stock. Barclays upped their price objective on shares of Amgen from $300.00 to $315.00 and gave the company an “equal weight” rating in a research note on Monday, October 7th. Finally, Dbs Bank raised shares of Amgen to a “strong-buy” rating in a research report on Monday, September 16th. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $332.55.

Amgen Stock Up 0.4 %

Shares of Amgen stock opened at $316.98 on Friday. The firm has a market cap of $170.04 billion, a price-to-earnings ratio of 45.28, a P/E/G ratio of 2.86 and a beta of 0.61. The stock has a 50-day simple moving average of $325.49 and a 200-day simple moving average of $313.47. Amgen Inc. has a 52-week low of $249.70 and a 52-week high of $346.85. The company has a debt-to-equity ratio of 9.64, a current ratio of 1.26 and a quick ratio of 0.89.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, August 6th. The medical research company reported $4.97 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.01 by ($0.04). Amgen had a net margin of 10.12% and a return on equity of 161.72%. The business had revenue of $8.39 billion during the quarter, compared to analyst estimates of $8.35 billion. During the same quarter last year, the firm earned $5.00 earnings per share. Amgen’s revenue was up 20.1% compared to the same quarter last year. On average, equities research analysts expect that Amgen Inc. will post 19.49 earnings per share for the current fiscal year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 9th. Shareholders of record on Monday, November 18th will be given a dividend of $2.25 per share. This represents a $9.00 annualized dividend and a yield of 2.84%. Amgen’s payout ratio is 128.57%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.